الفهرس 
List of ContentsIOnly 14 pages are availabe for public view
 |  | from | 135 |  |  |
| | | from | 135 | | |
Abstract
Objective: The aim of this study was to compare the levels of inflammatory markers IL-1β,IL-36β and IL6 in serum and gingival crevicular fluid, in type 2 diabetic and non-diabetic patients with chronic periodontitis, before and after phase I therapy. Subjects and Methods: A total of fifty subjects was included in this study; 20 Type 2 diabetic subjects with chronic periodontitis(group I) and 20 systemically healthy subjects with chronic periodontitis(group II) in addition to 10 systemically healthy subjects with clinically healthy gingiva as a control group (group III). The nonsurgical periodontal therapy was done to both group I and group II .Periodontal parameters, including plaque index, gingival index, bleeding on probing, probing depth and the clinical attachment level, in all the sites were recorded. GCF and serum were collected from all individuals included in the study; the first sample was collected from all groups (study and control) before phase I therapy. The second sample was collected 6 weeks after phase I therapy from group I& group II . Levels of IL-1β, IL-36β and IL-6 in GCF and serum were quantified using ELISA. The results:- showed statistical significant reduction in total levels of IL-1β ,IL-36β and IL-6 in serum and GCF in both groups; Type 2 diabetes with chronic periodontitis group (I) and systemically healthy with periodontitis group (II) after phase I therapy. Results also showed all clinical parameters were significantly improved after the phase I periodontal therapy in both groups I &II (p<0.001)